Delpor Logo

Company Summary

Delpor’s technologies enable the sustained release of proteins and peptides as well as small molecules through a small non-mechanical (passive) subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. We have the capability to deliver small molecules and biopharmaceuticals within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. The benefits of such delivery include improved patient adherence to the medication, as well as patient convenience in the case where frequent subcutaneous injections are required. Our unique delivery technologies also result in fewer AEs and improved efficacy due to a smoother pharmacokinetic profile without any peaks or troughs.

Year Founded:  2009

Key Executives:
• Tassos Nicolaou, Founder & CEO
• Frank Martin, PhD, Founder & CSO

Location:  San Francisco, CA


Company Status:  Private

Year Invested:  2016

Investment Status:  Current

Board Member:
Todd Thomson